Dateline City:
KENILWORTH, N.J. & LEXINGTON, Mass.
Acquisition Augments Mercks Strong Foundation and Opportunity for Growth in Hospital Acute Care Market
KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) today announced that the
companies have entered into a definitive agreement under which Merck
will acquire Cubist for $102 per share in cash, which represents a 35
percent premium to Cubists average stock price for the most recent five
trading days.
Language:
English
Contact:
MerckMedia Contacts:Lainie Keller, 908-406-1459orSteve Cragle, 908-740-1801orInvestor Contacts:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879orCubistMedia Contact:Julie DiCarlo, 781-860-8063orInvestor Contact:Eileen C. McIntyre, 781-860-8100
Ticker Slug:
Ticker: MRK Exchange: NYSE
Ticker: CBST Exchange: NASDAQ
read more